Beryllium-induced tumor necrosis factor-alpha production by CD4+ T cells is mediated by HLA-DP.
D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001607:Berylliosis / Q000276:immunology* / Q000378:metabolism / Q000503:physiopathology; D001608:Beryllium / Q000009:adverse effects*; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects / Q000276:immunology; D016207:Cytokines / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D005260:Female; D006682:HLA-DP Antigens / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism*; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D008297:Male; D008875:Middle Aged; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D011948:Receptors, Antigen, T-Cell / Q000187:drug effects / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis* / Q000235:genetics / Q000276:immunology; D015854:Up-Regulation / Q000187:drug effects / Q000235:genetics / Q000276:immunology
D000911:Antibodies, Monoclonal; D016207:Cytokines; D006682:HLA-DP Antigens; D018836:Inflammation Mediators; D012333:RNA, Messenger; D011948:Receptors, Antigen, T-Cell; D014409:Tumor Necrosis Factor-alpha; D001608:Beryllium